<DOC>
	<DOCNO>NCT02673554</DOCNO>
	<brief_summary>In patient type 2 diabetes , incretin hormone glucose-dependent insulinotropic polypeptide ( GIP ) lose insulinotropic activity , continuous versus bolus administration . The design two-way crossover design compare repeat bolus injection continuous infusion GIP hyperglycaemic clamp condition . Patients age- gender- weight-matched type 2 diabetes , first degree relative patient , healthy subject . Investigators perform : 1 . Oral glucose challenge ; 2. hyperglycemic clamp ( 8.5 mmol/l ) two repeat GIP bolus administration ( 50 pmol/kg body weight 30 120 min ) ; 3. hyperglycemic clamp continuous administration GIP ( 2 pmol.kg-1.min-1 30-180 min ) . To answer question , whether rapid tachyphylaxis occur regard insulinotropic action GIP , investigator study type 2-diabetic patient , first-degree relative , healthy control hyperglycaemic clamp condition two GIP bolus injection 90 min apart , compare continue intravenous infusion GIP .</brief_summary>
	<brief_title>The Reduced Insulinotropic Effect Continuous Infusion Relative Bolus Injection GIP</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Gastric Inhibitory Polypeptide</mesh_term>
	<criteria>Exclusion pregnancy Exclusion impair glucose tolerance type 2 diabetes metabolical healthy subject current diagnosis type 2 diabetes accord guideline German Diabetes Association ( DDG ) ( Kerner et al . 2001 ) subject diabetes group fast glucose ≤ 150 mg/dl Bodymassindex ≥ 20 kg/m² Written consent Type 1 diabetes Impaired glucose tolerance Type 2 diabetes metabolical healthy subject Ketone body urine diagnostics least ++ Acidosis Fasting blood glucose &gt; 150 mg/dl Bodymassindex &lt; 20 kg/m² No write consent Pregnancy unsafe contraception woman menopause Active malignancy Angina current , unsolved clinical problem Inadequately treat untreated arterial hypertension ( &gt; 160 mmHg systolic / &gt; 95 mmHg diastolic ) Infection / fever &gt; 37.5 ° C Treatment glucocorticoid Insulin therapy within last three month Anemia hemoglobin level &lt; 12 g/dl Liver function limitation Renal impairment ( serum creatinine &gt; 1.5 mg/dl ) Alcohol drug abuse Participation clinical trial last 3 month Inability unwillingness comply requirement Protocol Known hypersensitivity GIP</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Glucose-dependent Insulinotropic Polypeptide ( GIP )</keyword>
	<keyword>Glucagon-Like Peptide 1 ( GLP-1 )</keyword>
	<keyword>Incretin</keyword>
	<keyword>Insulin secretion</keyword>
	<keyword>Tachyphylaxis</keyword>
</DOC>